IDH2 and astrocytoma (excluding glioblastoma): Pekmezci et al. (2017) studied the status of both TERT and ATRX mutations along with their prognostic values in cohorts including grade II/III astrocytomas. The wildtype (WT) TERT group was associated with good prognosis only in IDH1/IDH2 WT (IDH-WT) grade II/III astrocytomas. However, in those groups with IDH mutations, including AO, TERT promoter mutation status was not a statistically significant prognostic factor (Dahlin et al., 2016).